Dermatol. praxi. 2014;8(2):49-52

Diagnostic and treatment recommendations for pemphigus

doc.MUDr.Hana Jedličková, Ph.D.
I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně

Pemphigus vulgaris is one of the most serious autoimmune dermatoses. The success of treatment depends on accurate diagnosis and

choice of immunosuppressive drugs with minimal side effects. Current therapies are based on the recommendations prepared by the

European Recommendations of the European Dermatology Forum (EDF).

dapsone, immunoadsorption.

Keywords: pemphigus, therapy, guidelines, corticosteroids, mycophenolate mofetil, rituximab, azathioprine, cyclophosphamide,

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jedličková H. Diagnostic and treatment recommendations for pemphigus. Dermatol. praxi. 2014;8(2):49-52.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab Exerts a Dual Effect in Pemphigus vulgaris. J Invest Dermatol. 2008; 128: 2745-2747. Go to original source... Go to PubMed...
    2. Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39: 609-616. Go to original source... Go to PubMed...
    3. Enk A, Fierlbeck G, French L, Girolomoni G, Hertl M, Jolles S, Joly P, Karpati S, Messer G, Meurer M, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D, Aberer W, Bagot M, Braathen L, Chimenti S, Diaz-Perez JL, Hegyi V, Kemény L, Korting HC, Murphy G, Neumann M, Ormerod T, Ranki A, Wojnarowska F, Sterry W. European Dermatology Forum Guideline Subcommittee Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol. 2009; 19: 90-98. Go to original source...
    4. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-937. Go to original source... Go to PubMed...
    5. Hertl M, Jedličková H, Karpati S, Marinovic B, Uzun S, Yayli S, Mimouni D, Borradori L, Feliciani C, Ioannides D, Joly P, Kowalewski C, Zambruno G, Zillikens D, Jonkman M. Development of European Guidelines Autoimmune Bullous Diseases/guided by the European Dermatology Forum (EDF) in cooperation with European Academy of Dermatology and Venerology (EADV)/Pemphigus. S2 Guideline for diagnosis and treatment. In: European Dermatology Forum 2013, www.euroderm.org/images/stories/guidelines/Autoimmune-bullous-diseases-Pemphigus-S2a.pdf. Go to original source...
    6. Jedličková H. Imunofluorescenční vyšetření v dermatologii. Čes-slov. Derm 2011; 86(4): 175-184.
    7. Jedličková H. Onemocnění skupiny pemfigu. Standard léčebného plánu v: Programy kvality a standardy léčebných postupů, Derm10.Verlag Dashöfer, Praha. 2003-2013, aktualizované on-line vydání http://www.mediprofi.cz/33/derm-10-onemocneni-skupiny-pemfigu.
    8. Joly P, Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S. [Pemphigus. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Societe Francaise de Dermatologie]. Ann Dermatol Venereol 2011; 138(3): 252-258. Go to original source... Go to PubMed...
    9. Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011; 64(5): 903-908. Go to original source... Go to PubMed...
    10. Murrell DF, Dick S, Ahmed RA, et al. Consensus statement of definition of disease, end points, and therapeutic response for pemphigus patients. J Am Acad Dermatol. 2008; 58: 1043-1046. Go to original source... Go to PubMed...
    11. Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem. 2000; 275(38): 29466-29476. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.